

A RANDOMIZED CONTROLLED TRIAL: STANDARD EUS-FNA VERSUS CONTRAST-ENHANCED EUS-FNA IN DIAGNOSIS OF BILIARY DUCT TUMORS

Ioana Rusu

UEG Week Copenhagen 2023

Poster

Hepatobiliary

October 15, 2023

A randomized controlled trial comparing contrast-enhanced EUS-FNA to standard EUS-FNA for diagnosing biliary duct tumors found no significant difference in diagnostic performance between the two techniques.

KEY POINTS

- 61 jaundiced patients with biliary duct tumors were randomized to standard EUS-FNA (n=31) or contrast-enhanced EUS-FNA (n=30), with final diagnoses including cholangiocarcinoma (n=37), pancreatic ductal carcinoma (n=12), other malignancy (n=3), and benign lesions (n=9).
- Diagnostic sensitivity, specificity, and accuracy were 84%, 100%, and 87% for standard EUS-FNA versus 82%, 100%, and 83% for contrast-enhanced EUS-FNA, with no significant difference between groups (p=0.22).
- Plastic biliary stent placement and tumor location did not influence diagnostic results in either group.
- Contrast-enhanced EUS showed hyperenhancement with rapid wash-out in 81.8% of cholangiocarcinoma cases, though not all cholangiocarcinomas demonstrated this pattern.
- This study is relevant to gastroenterologists and endoscopists evaluating the role of contrast-enhanced techniques in tissue acquisition for biliary duct tumors.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/114d4b92-743c-11ee-a739-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.